-
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
Wednesday, September 13, 2023 - 12:31pm | 913By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology advancing but not with our wellbeing in mind as everything seems to be thriving...
-
CSPC Pharma Wins China's mRNA Vaccine Race, But Just Not Fast Enough
Wednesday, March 29, 2023 - 9:06am | 1205Key Takeaways: News of marketing approval for China’s first mRNA vaccine falls flat with investors, who worry the drug is being rushed to market before Phase 3 trials are complete As the pandemic abates, the market for the vaccine is shrinking rapidly By Ellie Si Timing is everything, so...
-
Tesla, Amazon, Moderna, United Airlines, Goldman Sachs: Why These 5 Stocks Are Drawing Heavy Attention Today
Tuesday, January 17, 2023 - 9:02pm | 461Major Wall Street indices closed mixed on Tuesday, with the Dow Jones falling over 1%, pressured by Goldman Sachs Group Inc (NYSE: GS) earnings. The S&P 500 closed marginally lower at 0.2%, while the Nasdaq Composite ended the session 0.14% higher. Meanwhile, here are the five stocks that...
-
5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More
Monday, September 6, 2021 - 9:30am | 918Global merger and acquisition activity topped $1 trillion in the second quarter of 2021, with the U.S alone topping $500 billion. This was the third quarter in a row that this happened globally and in the U.S. The second quarter started strong with four of the five largest deals announced in the...
-
Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US
Tuesday, August 3, 2021 - 9:52am | 260The FDA granted Fast Track designation Moderna Inc's (NASDAQ: MRNA) mRNA-1345, its investigational single-dose mRNA vaccine against the respiratory syncytial virus (RSV) in adults older than 60 years of age. The respiratory syncytial virus is a common respiratory virus that...
-
Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights
Tuesday, August 3, 2021 - 6:04am | 421A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 billion buyout for Translate Bio. Sanofi will pay $38 in cash for each...
-
Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam
Monday, August 2, 2021 - 11:22am | 281The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19 vaccine candidate targeting variants of concern. The ARCT-154 Phase 1/2/3 clinical study is a randomized, observer-blind...
-
Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna
Monday, August 2, 2021 - 8:48am | 152Autolus Therapeutics plc (NASDAQ: AUTL) has granted Moderna Inc (NASDAQ: MRNA) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets. Autolus would be eligible to receive an...
-
What Investors Should Know About Ginkgo Bioworks SPAC Deal: 'Cell Programming Has The Potential To Impact Every Physical Goods Industry'
Tuesday, May 11, 2021 - 3:29pm | 656A well seasoned SPAC management team announced a SPAC deal Tuesday to bring a cell programming company public. The SPAC Deal: Ginkgo Bioworks is going public in a SPAC deal with Soaring Eagle Acquisition Corp (NASDAQ: SRNG) that values the company at a pre money equity value of $15 billion. Soaring...